Emtricitabine/rilpivirine/tenofovir (Eviplera®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000602
English
Authors' recommendations:
Emtricitabine/rilpivirine/tenofovir (Eviplera®) is recommended as an option for use within NHS for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load = 100,000 HIV-1 RNA copies/ml.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=195433&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- HIV Infections
- Drug Therapy, Combination
- Anti-HIV Agents
- Rilpivirine
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- HIV
- Reverse Transcriptase Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.